FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2547539042> ?p ?o ?g. }

• W2547539042 endingPage "336.e2" @default.
• W2547539042 startingPage "327" @default.
• W2547539042 abstract "Study objective Parenteral olanzapine is an emerging therapy for a variety of conditions in the emergency department (ED). Intramuscular administration is standard; however, intravenous administration has been proposed as a safe alternative route. We investigate the safety and efficacy of both intramuscular and intravenous olanzapine in the ED when used for a variety of indications. Methods This was a prospective observational study of patients presenting to an urban Level I trauma center ED. Trained research associates screened the ED for patients receiving parenteral olanzapine. The primary outcome of the study was incidence of respiratory depression measured with standard markers. Secondary outcomes included use of additional doses or sedatives, corrected QT interval (QTc) data, time to nadir sedation, adverse events, and physician assessment of efficacy. Results There were 784 patients included in the final analysis. Intravenous olanzapine was administered to 295 patients; 489 received intramuscular olanzapine. Respiratory depression occurred in 11 of 295 patients (3.7%; 95% confidence interval [CI] 1.6% to 5.9%) receiving intravenous olanzapine and 10 of 489 (2.0%; 95% CI 0.8% to 3.3%) receiving intramuscular olanzapine. Seven patients required intubation, 2 in the intravenous group and 5 in the intramuscular group. Nonrespiratory complications occurred in 8 patients, 6 of 295 (2.0%; 95% CI 0.4% to 3.6%) in the intravenous group and 2 of 489 (0.4%; 95% CI 0% to 0.96%) in the intramuscular group. Dysrhythmias were isolated to 2 episodes of bradycardia requiring only supportive care. Conclusion These data suggest that, with proper monitoring, administration of olanzapine, both intramuscular and intravenous, is safe for several indications in the ED. Parenteral olanzapine is an emerging therapy for a variety of conditions in the emergency department (ED). Intramuscular administration is standard; however, intravenous administration has been proposed as a safe alternative route. We investigate the safety and efficacy of both intramuscular and intravenous olanzapine in the ED when used for a variety of indications. This was a prospective observational study of patients presenting to an urban Level I trauma center ED. Trained research associates screened the ED for patients receiving parenteral olanzapine. The primary outcome of the study was incidence of respiratory depression measured with standard markers. Secondary outcomes included use of additional doses or sedatives, corrected QT interval (QTc) data, time to nadir sedation, adverse events, and physician assessment of efficacy. There were 784 patients included in the final analysis. Intravenous olanzapine was administered to 295 patients; 489 received intramuscular olanzapine. Respiratory depression occurred in 11 of 295 patients (3.7%; 95% confidence interval [CI] 1.6% to 5.9%) receiving intravenous olanzapine and 10 of 489 (2.0%; 95% CI 0.8% to 3.3%) receiving intramuscular olanzapine. Seven patients required intubation, 2 in the intravenous group and 5 in the intramuscular group. Nonrespiratory complications occurred in 8 patients, 6 of 295 (2.0%; 95% CI 0.4% to 3.6%) in the intravenous group and 2 of 489 (0.4%; 95% CI 0% to 0.96%) in the intramuscular group. Dysrhythmias were isolated to 2 episodes of bradycardia requiring only supportive care. These data suggest that, with proper monitoring, administration of olanzapine, both intramuscular and intravenous, is safe for several indications in the ED." @default.
• W2547539042 created "2016-11-11" @default.
• W2547539042 creator A5012899273 @default.
• W2547539042 creator A5022767181 @default.
• W2547539042 creator A5044349620 @default.
• W2547539042 creator A5049386972 @default.
• W2547539042 creator A5062320586 @default.
• W2547539042 creator A5075900301 @default.
• W2547539042 creator A5085811706 @default.
• W2547539042 date "2017-03-01" @default.
• W2547539042 modified "2023-10-03" @default.
• W2547539042 title "A Prospective Observational Study of Patients Receiving Intravenous and Intramuscular Olanzapine in the Emergency Department" @default.
• W2547539042 cites W1971472136 @default.
• W2547539042 cites W1981587818 @default.
• W2547539042 cites W1983452337 @default.
• W2547539042 cites W2021799665 @default.
• W2547539042 cites W2029861423 @default.
• W2547539042 cites W2030136010 @default.
• W2547539042 cites W2040982410 @default.
• W2547539042 cites W2041614404 @default.
• W2547539042 cites W2043929905 @default.
• W2547539042 cites W2047791862 @default.
• W2547539042 cites W2050056114 @default.
• W2547539042 cites W2055125378 @default.
• W2547539042 cites W2062665760 @default.
• W2547539042 cites W2089628722 @default.
• W2547539042 cites W2090815859 @default.
• W2547539042 cites W2091423706 @default.
• W2547539042 cites W2092224096 @default.
• W2547539042 cites W2117432551 @default.
• W2547539042 cites W2154028656 @default.
• W2547539042 cites W2170334502 @default.
• W2547539042 cites W2205962720 @default.
• W2547539042 cites W4230503368 @default.
• W2547539042 doi "https://doi.org/10.1016/j.annemergmed.2016.08.008" @default.
• W2547539042 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27823873" @default.
• W2547539042 hasPublicationYear "2017" @default.
• W2547539042 type Work @default.
• W2547539042 sameAs 2547539042 @default.
• W2547539042 citedByCount "38" @default.
• W2547539042 countsByYear W25475390422017 @default.
• W2547539042 countsByYear W25475390422018 @default.
• W2547539042 countsByYear W25475390422019 @default.
• W2547539042 countsByYear W25475390422020 @default.
• W2547539042 countsByYear W25475390422021 @default.
• W2547539042 countsByYear W25475390422022 @default.
• W2547539042 countsByYear W25475390422023 @default.
• W2547539042 crossrefType "journal-article" @default.
• W2547539042 hasAuthorship W2547539042A5012899273 @default.
• W2547539042 hasAuthorship W2547539042A5022767181 @default.
• W2547539042 hasAuthorship W2547539042A5044349620 @default.
• W2547539042 hasAuthorship W2547539042A5049386972 @default.
• W2547539042 hasAuthorship W2547539042A5062320586 @default.
• W2547539042 hasAuthorship W2547539042A5075900301 @default.
• W2547539042 hasAuthorship W2547539042A5085811706 @default.
• W2547539042 hasConcept C118552586 @default.
• W2547539042 hasConcept C120665830 @default.
• W2547539042 hasConcept C121332964 @default.
• W2547539042 hasConcept C126322002 @default.
• W2547539042 hasConcept C197934379 @default.
• W2547539042 hasConcept C23131810 @default.
• W2547539042 hasConcept C2776412080 @default.
• W2547539042 hasConcept C2776619155 @default.
• W2547539042 hasConcept C2778716859 @default.
• W2547539042 hasConcept C2780724011 @default.
• W2547539042 hasConcept C42219234 @default.
• W2547539042 hasConcept C44249647 @default.
• W2547539042 hasConcept C61511704 @default.
• W2547539042 hasConcept C71924100 @default.
• W2547539042 hasConceptScore W2547539042C118552586 @default.
• W2547539042 hasConceptScore W2547539042C120665830 @default.
• W2547539042 hasConceptScore W2547539042C121332964 @default.
• W2547539042 hasConceptScore W2547539042C126322002 @default.
• W2547539042 hasConceptScore W2547539042C197934379 @default.
• W2547539042 hasConceptScore W2547539042C23131810 @default.
• W2547539042 hasConceptScore W2547539042C2776412080 @default.
• W2547539042 hasConceptScore W2547539042C2776619155 @default.
• W2547539042 hasConceptScore W2547539042C2778716859 @default.
• W2547539042 hasConceptScore W2547539042C2780724011 @default.
• W2547539042 hasConceptScore W2547539042C42219234 @default.
• W2547539042 hasConceptScore W2547539042C44249647 @default.
• W2547539042 hasConceptScore W2547539042C61511704 @default.
• W2547539042 hasConceptScore W2547539042C71924100 @default.
• W2547539042 hasIssue "3" @default.
• W2547539042 hasLocation W25475390421 @default.
• W2547539042 hasLocation W25475390422 @default.
• W2547539042 hasOpenAccess W2547539042 @default.
• W2547539042 hasPrimaryLocation W25475390421 @default.
• W2547539042 hasRelatedWork W1580426574 @default.
• W2547539042 hasRelatedWork W2026095104 @default.
• W2547539042 hasRelatedWork W2089620537 @default.
• W2547539042 hasRelatedWork W2099369673 @default.
• W2547539042 hasRelatedWork W2275480158 @default.
• W2547539042 hasRelatedWork W2371214482 @default.
• W2547539042 hasRelatedWork W2510700473 @default.
• W2547539042 hasRelatedWork W3095306390 @default.
• W2547539042 hasRelatedWork W4238089809 @default.
• W2547539042 hasRelatedWork W4238308949 @default.

• next